Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

NCT06652438 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

415

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia, Adult

Interventions

DRUG: Revumenib
DRUG: Placebo

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]
[object Object]